

Aan: 5.1.2e, 5.1.2e, (5.1.2e) <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e, 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e, 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e, 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e, 5.1.3e, 5.1.2e <5.1.2e@minvws.nl>

CC: 5.1.2e, 5.1.2e, (5.1.2e) <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e <5.1.2e@minvws.nl>

Onderwerp: RE: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

Ter info.

Vooral interessant, vind ik, dat deze resultaten zijn geboekt met een 4-weken prikinterval! Rechtvaardigt in mijn ogen weer een vervolgvraag richting GR. Eens? Want dat zou in alle prikschema's volgens mij echt wel helpen.

Groet, 5.1.2e

Van: 5.1.2e, 5.1.2e <5.1.2e@astrazeneca.com>

Verzonden: maandag 22 maart 2021 08:18

Aan: Minister van VWS <5.1.2e@minvws.nl>; Minister van VWS <5.1.2e@minvws.nl>

CC: 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e, (5.1.2e) <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e, <5.1.2e@minvws.nl>; 5.1.2e, 5.1.2e <5.1.2e@gmail.com>; 5.1.2e, 5.1.2e <5.1.2e@astrazeneca.com>

Onderwerp: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

Dear Minister de Jonge,

Dear Minister van Ark,

I wanted to keep you informed that AstraZeneca has just announced positive high-level results from an interim analysis of the AstraZeneca US Phase III trials of AZD1222.

The data show that the vaccine demonstrated statistically significant **vaccine efficacy of 79% at preventing symptomatic COVID-19** and **100% efficacy at preventing severe disease and hospitalisation**. This US Phase III trial included two doses administered at a 4 week interval.

- Vaccine efficacy was **consistent across ethnicity and age**. Notably, vaccine efficacy was **80% in participants aged 65 years and over**, who represented approximately 20% of participants.
- This interim safety and efficacy analysis was based on 32,449 participants across 88 trial centres in the US, Peru and Chile accruing 141 symptomatic cases of COVID-19. The vaccine was **well tolerated**, and the data safety monitoring board (DSMB) identified **no safety concerns** related to the vaccine.
- The DSMB also conducted a **specific review of thromboembolic events** across the US trial data and found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for cerebral venous sinus thrombosis (CVST) found no events in this trial.

These results confirm this vaccine is well tolerated and highly effective against COVID-19 across all adult age groups.

Please find below the official company announcement with further information. Please do not hesitate to contact me should you have any follow-up questions.

Sincerely,

5.1.2e

5.1.2e
Netherlands

AstraZeneca


M: +31 (0)6 5.1.2e

5.1.2e @astrazeneca.com

PA: 5.1.2e T: +31 (0)79 5.1.2e

5.1.2e @astrazeneca.com

[Click here to view online](#)



AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

22 March 2021

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.

Read more

[RSS Feed](#) [Follow us on Twitter](#) [Follow us on LinkedIn](#)

[Legal notice and Terms of Use](#) | [Privacy policy](#) | [Cookie policy](#) | [Site map](#) | © AstraZeneca 2021

For more information please visit astrazeneca.com.

If you would like to unsubscribe please [click here](#).

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability